Role of sevelamer carbonate in the treatment of hyperphosphatemia in the chronic kidney disease patients on hemodialysis therapy

Abstract EN

Objective: Hyperphosphataemia is a frequent complication in patients with chronic kidney disease (CKD), particularly in those with end-stage renal disease, and there is considerable evidence that inadequate phosphorus control is associated with increased morbidity and mortality.

The aim of this study and physical examination at baseline, all patients were taken calcium carbonate tablets, and half of them were received sevelamer carbonate tablets for a period of six months (24 weeks).

The investigations include blood urea, serum creatinine, calcium, phosphorus, alkaline phosphatase and parathyroid hormone.

Results: Sevelamer carbonate plus calcium carbonate made a significant reduction in serum phosphorus, parathyroid hormone and serum calcium levels when compared with calcium carbonate received patients, serum phosphorus correlated positively with s.PTH while negatively with s.Ca.

Conclusions: Sevelamer carbonate was effective and safe in hyperphosphataemia patients with chronic renal failure on hemodialysis.